University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Jeroen Roose, PhD

Jeroen Roose, PhD

Professor, Department of Anatomy, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Research Summary

I obtained my PhD in The Netherlands where I investigated Wnt signaling and cancer in the lab of Dr. Hans Clevers. I subsequently studied Ras signaling in lympohcytes during my postdoc in the lab of Dr. Arthur Weiss at UCSF. Since 2007 I built my own research group as an independent investigator in the department of Anatomy at UCSF. I am currently a tenured Associate Professor with a team of staff members, graduate students, postdoctoral fellows, and Master’s students. Our focus is on Ras-kinase signaling an implications of signal alterations in human disease,

Half of my group currently focuses on various aspects of Ras signaling and cancer. We have published on the leukemic role of the Ras activator Rasgrp1 in both T cell leukemia and in myeloid leukemia. We reported on two biochemically distinct oncogenic Ras signals in T cell leukemia. We continue this research area with the goal of improving molecular therapy for leukemia patients. We expanded our research to carcinomas and reported that the EGFR sends not only growth-stimulatory cues in colorectal cancer but also growth-restricting signals, depending on the use of the SOS1- or RasGRP1- Ras activators.

We are part of the Biomedical Science (BMS) Graduate Program, the Immunology Program, the Helen Diller Family Comprehensive Cancer Center, and the Stem Cell Center. For more information on research directions, projects, and publications, please visit our website at


University of Utrecht, The Netherlands, MS, 1993, Medical Biology
University of Utrecht, The Netherlands, PhD, 1999, Immunology/Transcription
University of Utrecht, The Netherlands, Fellowship, 1997-1999, Immunology/Transcription
University of California San Francisco, San Francisco, Fellowship, 1999-2004, Immunology/Signaling

Professional Experience

  • 2004-2006
    Adjunct Instructor, Div. of Rheumatology, Dept. of Medicine, UCSF, San Francisco
  • 2006-2007
    Assistant Adjunct Professor, Div. of Rheumatology, Dept. of Medicine, UCSF, San Francisco
  • 2007-2014
    Assistant Professor, Dept. of Anatomy, School of Medicine, UCSF, San Francisco
  • 2014-2018
    Associate Professor, Dept. of Anatomy, School of Medicine, UCSF, San Francisco
  • 2018-present
    Professor, Dept. of Anatomy, School of Medicine, UCSF, San Francisco

Honors & Awards

Past 5 years:

  • 2012
    Gabrielle's Angel Foundation Award
  • 2013
    9th annual Mentoring award by the UCSF PSA (Postdoctoral Scholar’s Association)
  • 2014
    R01 Award (NIH; NIAID)
  • 2015
    R01 Award (NIH; NCI)
  • 2015
    Alex's Lemonade Stand Foundation Innovator Award
  • 2015
    R01 Award (NIH; NHLBI)
  • 2016
    Renewal P01 Award (NIH; NIAID)

Selected Publications

  1. Samocha A, Doh H, Kessenbrock K, Roose JP. Unraveling Heterogeneity in Epithelial Cell Fates of the Mammary Gland and Breast Cancer. Cancers (Basel). 2019 Sep 24; 11(10).
    View on PubMed
  2. Kondo Y, Ognjenovic J, Banerjee S, Karandur D, Merk A, Kulhanek K, Wong K, Roose JP, Subramaniam S, Kuriyan J. Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases. Science. 2019 10 04; 366(6461):109-115.
    View on PubMed
  3. Myers DR, Wheeler B, Roose JP. mTOR and other effector kinase signals that impact T cell function and activity. Immunol Rev. 2019 09; 291(1):134-153.
    View on PubMed
  4. Jun JE, Kulhanek KR, Chen H, Chakraborty A, Roose JP. Alternative ZAP70-p38 signals prime a classical p38 pathway through LAT and SOS to support regulatory T cell differentiation. Sci Signal. 2019 Jul 23; 12(591).
    View on PubMed
  5. Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. JCI Insight. 2019 Jun 25; 5.
    View on PubMed
  6. Myers DR, Norlin E, Vercoulen Y, Roose JP. Active Tonic mTORC1 Signals Shape Baseline Translation in Naive T Cells. Cell Rep. 2019 May 07; 27(6):1858-1874.e6.
    View on PubMed
  7. Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Rep. 2019 Apr 09; 27(2):631-647.e5.
    View on PubMed
  8. Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PLoS One. 2018; 13(5):e0193849.
    View on PubMed
  9. Vercoulen Y, Kondo Y, Iwig JS, Janssen AB, White KA, Amini M, Barber DL, Kuriyan J, Roose JP. A Histidine pH sensor regulates activation of the Ras-specific guanine nucleotide exchange factor RasGRP1. Elife. 2017 09 27; 6.
    View on PubMed
  10. Myers DR, Zikherman J, Roose JP. Tonic Signals: Why Do Lymphocytes Bother? Trends Immunol. 2017 11; 38(11):844-857.
    View on PubMed
  11. Myers DR, Lau T, Markegard E, Lim HW, Kasler H, Zhu M, Barczak A, Huizar JP, Zikherman J, Erle DJ, Zhang W, Verdin E, Roose JP. Tonic LAT-HDAC7 Signals Sustain Nur77 and Irf4 Expression to Tune Naive CD4 T Cells. Cell Rep. 2017 05 23; 19(8):1558-1571.
    View on PubMed
  12. Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, Coupland SE, Roose JP, Bastian BC. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell. 2017 05 08; 31(5):685-696.e6.
    View on PubMed
  13. Roose JP. Lost GRP on cytotoxicity? Nat Immunol. 2016 11 16; 17(12):1339-1340.
    View on PubMed
  14. Christensen SM, Tu HL, Jun JE, Alvarez S, Triplet MG, Iwig JS, Yadav KK, Bar-Sagi D, Roose JP, Groves JT. One-way membrane trafficking of SOS in receptor-triggered Ras activation. Nat Struct Mol Biol. 2016 09; 23(9):838-46.
    View on PubMed
  15. Mues M, Roose JP. Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle. Small GTPases. 2017 01 02; 8(1):20-25.
    View on PubMed
  16. Jeroen Roose, Philippe Depeille, Robert S. Warren. Suppressive signals in colorectal cancer: RasGRP1 a new marker for anti-EGFR therapy?. Journal of Clinical Oncology. 2016 Feb 1; 34(4_suppl):625-625.
    View on PubMed
  17. Rooney GE, Goodwin AF, Depeille P, Sharir A, Schofield CM, Yeh E, Roose JP, Klein OD, Rauen KA, Weiss LA, Ullian EM. Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome. J Neurosci. 2016 Jan 06; 36(1):142-52.
    View on PubMed
  18. Darienne R. Myers, Jeroen P. Roose. Kinase and Phosphatase Effector Pathways in T Cells. Encyclopedia of Immunobiology. 2016 Jan 1; 25-37.
    View on PubMed
  19. Ksionda O, Melton AA, Bache J, Tenhagen M, Bakker J, Harvey R, Winter SS, Rubio I, Roose JP. RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines. Oncogene. 2016 07 14; 35(28):3658-68.
    View on PubMed
  20. Depeille P, Warren RS, Roose JP. Unexpected insights for anti-EGFR cancer therapy. Oncotarget. 2015 Aug 07; 6(22):18746-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI